finance
FDA Leadership Changes After Commissioner Departure
Marty Makary has left the position of FDA commissioner. An acting replacement now leads the agency that oversees medicines, vaccines, food, and medical devices.
May 18, 2:54 PM·1m read1 source
forbes.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Marty Makary has stepped down as FDA commissioner. An acting replacement is now in charge of the agency. U.S. food supply. Career scientists and inspectors carry out most of the agency's daily work.
Commissioners set priorities and shape how the agency communicates decisions. They also influence how quickly the FDA acts on new treatments or safety concerns. Former FDA deputy commissioner Joshua Sharfstein stated that public trust depends on transparent processes and scientific review.
Vaccine policy, teen vaping, abortion medication, and accelerated drug approvals were among the issues during Makary's time in the role. Different groups raised concerns about the pace and transparency of some decisions. Patients, physicians, companies, and researchers rely on the FDA for consistent standards.
Leadership changes can affect how those standards are applied and how the public views the agency's work.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationModerate · 1 source
